Jian Huang

8PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyCancer cell biologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 10, 2024
Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.

Kaiwen Li, Wenlong Zhong, Jinhai Fan

|Jan 17, 2024
Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.

Yi Ouyang, Wenlong Zhong, Peiqi Xu

|Oct 17, 2023
Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.

Bo Wang, Ziwei Ou, Wenlong Zhong

|Sep 28, 2023
FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation.

Yi Ouyang, Ziwei Ou, Wenlong Zhong

|Aug 12, 2023
The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer.

Dong Yan, Qingqing He, Lu Pei

|Jun 13, 2023
Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.

Yuelong Chen, Ming Huang, Junlin Lu

Pageof 2

Frequent Collaborators

7 joint publications

Tianxin Lin

4 joint publications

Wenlong Zhong

2 joint publications

Longhao Xu

2 joint publications

Junyu Chen